Flagship Journal - European Medical Journal

Continue

Flagship Journal

Filter
EMJ 6.3 2021 Feature Image
6 Mins
21 Sep 2021

Review of Rifaximin: A Summary of the Current Evidence and Benefits Beyond Licensed Use

The benefits of rifaximin use continues to gather momentum, given its well-tolerated side-effect profile, and these require consideration.
EMJ 6.3 2021 Feature Image
10 Mins
21 Sep 2021

Which Biologic Therapies to Treat Active Rheumatoid Arthritis and When?

The arrival of biologic disease-modifying anti-arthritis drugs (bDMARD) has vastly improved the outcomes of patients
EMJ 6.3 2021 Feature Image
11 Mins
21 Sep 2021

Cardio-Metabolic Benefits of Walnuts in Type 2 Diabetes Mellitus: A Literature Review

In the USA, diabetes is a public health problem of epidemic proportions..
EMJ 6.3 2021 Feature Image
6 Mins
21 Sep 2021

A Case Report of Extensively Drug Resistant Typhoid in Karachi, Pakistan: A Major Health Concern to Curb the Outbreak

Salmonella typhi is a flagellated gram-negative bacterium that is rod shaped
Pancreatic β-Cell Senescence feature image
10 Mins
23 Mar 2021

Pancreatic β-Cell Senescence: Mechanisms and Association with Diabetes

Cellular senescence is a stress response to remove cell damage through immune system activation. The term ‘senescence’ was originally coined…
EMJ 6.1 Feature Image
11 Mins
23 Mar 2021

Addressing the Unmet Need in Treatment of Nonmelanoma Skin Cancers: Interviews with Two Key Opinion Leaders

Nonmelanoma skin cancers (NMSC) are a diverse group of cutaneous malignancies and are the most common forms of human neoplasia worldwide…
EMJ 6.1 Feature Image
15 Mins
23 Mar 2021

The Treatment Landscape of Atopic Dermatitis: Interviews with Three Consultant Dermatologists

Atopic dermatitis (AD), sometimes referred to as ‘atopic eczema’, is a common, chronic, pruritic, Type II inflammatory skin disease which is associated…
8 Mins
23 Mar 2021

Is CD37-Targeted Therapy a Viable Alternative in the Treatment of Diffuse Large B-cell Lymphoma? Interviews with Two Key Opinion Leaders

Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma and the most frequent non-Hodgkin lymphoma (NHL) in adults, accounting for 30–40%…